PROGRAM

Thursday, May 4

Educational Session: Genomics
15:00-17:00
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Molecular Tumor Board - Case Presentation
Lillian L. Siu and William C. Hahn

Clinical applications: Drug access and design of genotype-specific trials
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Opportunities for translational and discovery research: “Next-Gen” genomics
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion / Questions from audience
Lillian L. Siu and William C. Hahn

Break
17:00-17:30

Welcome and Opening Remarks
17:30-18:00

Welcome
Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil

Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned
18:00-19:30
Session Chair: Joao P.B. Viola, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

State of clinical success of immune checkpoints (new preclinical data on anti-PD-1 and ant PDL-1)
Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
PROGRAM

Abnormal ER stress responses as new immune checkpoints in cancer
Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, New York

Opening Reception
19:45-21:30

Friday, May 5

Keynote Lecture 1
08:30-09:15
Session Chair: Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil

The different facets of cervical cancer prevention
Luisa L. Villa, Fundação Faculdade de Medicina de S Paulo, São Paulo, SP, Brazil

Break
09:15-09:45

Plenary Session 2: Tumor Heterogeneity
09:45-10:45
Session Chair: Felipe C. Geyer, Memorial Sloan Kettering Cancer Center, New York, New York

The dynamics of cancer cell heterogeneity
Guido Lenz, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Intra-tumour genetic heterogeneity
Felipe C. Geyer

Break
10:45-11:00

Plenary Session 3: Hematological Malignancies
11:00-12:30
Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Epigenetic Mechanisms in Pathogenesis and Targeted Therapy for B-cell Lymphomas
Ari M. Melnick, Weill Cornell Medical College, New York, New York
PROGRAM

Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL)
Eduardo Magalhães Rego, University of São Paulo, Sao Paulo, Brazil

Novel therapeutic targets in multiple myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session A / Lunch
12:30-15:00

Plenary Session 4: Precision Medicine / Targeted and Combination Therapies / Drug Resistance
15:15-16:45
Session Chair: Oscar G. Arrieta, Instituto Nacional de Cancerología, Mexico City, Mexico

A systems approach to rational combination therapy with PARP inhibitors
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas

Evolution and clinical impact of co-occurring genetic alterations in lung cancer
Trever G. Bivona, University of California, San Francisco, California

Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Break
16:45-17:00

Plenary Session 5: Liquid Biopsies/Organoids/PDX
17:00-18:30
Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Circulating tumor DNA is a “liquid biopsy” for precision medicine: Basic concepts
Anamaria A. Camargo, Ludwig Institute for Research on Cancer, Sao Paulo, Brazil

Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Title to be announced
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts
PROGRAM

Saturday, May 6

Keynote Lecture 2
08:30-09:15
Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Defining a cancer dependencies map
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts

Break
09:15-09:45

Plenary Session 6: DNA Repair and PARP Inhibitors
09:45-11:15
Session Chair: Dyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil

Targeting DNA repair in cancer therapy
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts

Trapping PARP1 to kill cancer cells
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, Maryland

Methods for defining DNA repair defects in human cancer
Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York

Break
11:15-11:30

Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors
11:30-13:00
Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials
Matthew J. Ellis, Baylor College of Medicine, Houston, Texas

Targeting DNA repair dysfunction in prostate cancer
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

As of February 15, 2017
Program

Targeting DNA repair deficiencies in breast cancer
Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

Poster Session B / Lunch
13:00-15:00

Plenary Session 8: Oncogenes and Tumor Suppressors
15:15-16:45

Session Chair: Roger Chamma, University of São Paulo, Sao Paulo, Brazil

Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts

Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York

Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation
Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil

Break
16:45-17:00

Plenary Session 9: Epigenetics
17:00-18:30

Session Chair: Paulo M. Hoff, Centro de Oncologia, São Paulo, Brazil

The promise among the setbacks for epigenetic therapy in solid tumors
Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Defining cancer specific epigenomic signature associated with glioma progression
Houtan Noushmehr, University of São Paulo, Ribeirao Preto, São Paulo, Brazil

Closing Remarks
18:30-18:45

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil

As of February 15, 2017